Certified by Founder Lodge
Epsilogen Ltd
United Kingdom - Hammersmith
START UP
1 Disclosed Funding Rounds $16,370,899
0 Participating Investments
-
Founded date
2016
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours includi
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 10 ,2024 | Series B | $16,370,899 |
British Patient Capital
3B Future Health Fund I & II
Epidarex Capital
ALSA Ventures
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
WealthAi | $1,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
